Mosunetuzumab

Status:

Do Not Prescribe (DNP)

Decision Date:

June 2023

Comments

DNP:  NICE TA892 - Mosunetuzumab for treating relapsed or refractory follicular lymphoma. NHSE commissioned.

search again